IBS - Irritable Bowel Syndrome Clinical Trial
Official title:
Study to Evaluate the Efficacy of Poppi Apple Cider Vinegar Prebiotic Soda to Improve Gut Health In Participants
NCT number | NCT05418439 |
Other study ID # | 20229 Poppi |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2022 |
Est. completion date | May 1, 2022 |
Verified date | June 2022 |
Source | Drink Poppi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This exploratory observational trial provides the opportunity to gather information on the effect of daily consumption of Poppi Apple Cider Vinegar Prebiotic Soda on gut health and digestion.
Status | Completed |
Enrollment | 38 |
Est. completion date | May 1, 2022 |
Est. primary completion date | May 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Age: 18-45 - Male or Female - Must be in generally good health - BMI under 35 - Self-reported issues with gas, bloating, heartburn/acid reflux, abdominal pain or digestion - Willing to maintain their standard dietary pattern, activity level and body weight for the duration of the study Exclusion Criteria: - Severe chronic conditions, including oncological conditions or psychiatric disease - Currently pregnant, wanting to become pregnant, or breastfeeding for the duration of the study - Taking any prescription medication targeting the gut - Taking any supplements targeting the gut in the past month - Use of antibiotics in the past 3 months |
Country | Name | City | State |
---|---|---|---|
United States | Citruslabs | Santa Monica | California |
Lead Sponsor | Collaborator |
---|---|
Drink Poppi | Citruslabs |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in IBS symptoms [Time Frame: Baseline to 4 weeks) | Survey-based assessment (0-5 scale) of changes in IBS symptoms with higher scores representing an improved outcome. | 4 weeks | |
Primary | Change in bowel movements [Time Frame: Baseline to 4 weeks) | Survey-based assessment (0-5 scale) of changes in stool frequency and consistency (constipation vs. diarrhea vs. normal) with higher scores representing an improved outcome. | 4 weeks | |
Primary | Change in skin health [Time Frame: Baseline to 4 weeks) | Survey-based assessment (0-5 scale) of changes in perceived skin health with higher scores representing an improved outcome. | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05118243 -
Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance
|
N/A | |
Completed |
NCT04422327 -
The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome
|
Phase 1/Phase 2 | |
Recruiting |
NCT05178017 -
Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
|
N/A | |
Completed |
NCT05197413 -
Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms
|
N/A | |
Completed |
NCT04905524 -
Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)
|
N/A | |
Recruiting |
NCT06297785 -
Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS)
|
N/A | |
Recruiting |
NCT05874830 -
The Optimal Route of Fecal Microbiota Transplantation for Irritable Bowel Syndrome
|
N/A | |
Active, not recruiting |
NCT04723056 -
Zemedy Application for Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT05565612 -
Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT03131414 -
The IMAGINE-SPOR CIHR Chronic Disease Network
|
||
Completed |
NCT03333291 -
Fecal Transplantation in Patients With IBS
|
N/A | |
Completed |
NCT03449628 -
L. Casei DG® in Patients With Irritable Bowel Syndrome.
|
N/A | |
Recruiting |
NCT06215222 -
Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
|
||
Completed |
NCT05016596 -
Postprandial Lipids in IBS and Nutritional Treatment
|
N/A | |
Recruiting |
NCT04760353 -
The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT06426745 -
Split-dose Versus Single-dose Bowel Preparation for Colonoscopy
|
N/A | |
Recruiting |
NCT04217733 -
Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
|
Phase 3 | |
Completed |
NCT03178877 -
The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors
|
N/A | |
Recruiting |
NCT05990764 -
Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS)
|
N/A | |
Completed |
NCT03948854 -
Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients
|
N/A |